Abstract Library

#3976 Radiologic tumor border status can further stratify patients with pancreatic neuroendocrine tumor

Introduction: Recently, pattern-based classifications of the tumor border of pancreatic neuroendocrine tumor (PanNET) have been attempted by independent groups for patient stratification, which are only available in the post-operative setting.

Conference:

Presenting Author: Ahn B

Authors: Ahn B, Park H, Kim H, Hong S,

Keywords: pancreas, neuroendocrine tumor, pathologic tumor border, radiologic tumor border, survival, prognosis,

#3176 Tissue sample collection from patients with neuroendocrine tumor (NET) treated with peptide receptor radionuclide therapy (PRRT) for future blood disease research

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective treatment for patients with metastatic NET. However, the development of therapy-related myeloid neoplasms (t-MN) is an infrequent but serious complication. T-MN after PRRT occurs at higher frequency compared to other solid tumor chemotherapies and harbour unfavourable genetic mutations with poor treatment outcomes. Prospective data is needed to explore pre-existing genetic factors and predictive biomarkers to minimise t-MN risk.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kong G

Authors: Kong G, Michael M, Alipour R, Akhurst T, Hicks R,

Keywords: t-MN, PRRT, PRCRT, marrow biopsy,

#2897 Comparison of 68Ga-DOTATATE PET/CT for Assessment of Response to Peptide Receptor Radionuclide Therapy after 2 and 4 Cycles of 177Lu-DOTATATE: Preliminary Single Academic Center Experience

Introduction: Peptide receptor radionuclide therapy (PRRT) usually leads to stable rather than decreased lesion size in neuroendocrine tumors (NETs), therefore RECIST criteria are not used to assess early response to treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Song H, Kunz P, Fisher G, Franc B, Moradi F,

Keywords: PRRT, 68Ga-DOTATATE PET/CT, Neuroendocrine tumor,

#2866 Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Introduction: 177Lu-DOTATATE is an effective therapy for somatostatin receptor-positive neuroendocrine tumors (NETs). Often enough 177Lu-DOTATATE is used as the last treatment resort in advanced NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Song H, Kunz P, Franc B, Moradi F, Fisher G,

Keywords: 177Lu-DOTATATE, PRRT, 68Ga-DOTATATE PET, Chromogranin A, 68Ga-DOTATATE avid tumor volume,

#1391 Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) - A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT)

Introduction: Bulky disease from NET is an adverse prognostic factor for response to 177Lu-DOTA-octreotate (LuTate) PRCRT. 90Y-DOTA-octreotate (YTate) has more penetrating particulate emissions.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Kong G, Callahan J, Hofman M, Pattison D, Akhurst T,

Keywords: PRRT, Y-90,